Objectives To explore service user experiences of a 9-month cognitive behavioural therapy for command hallucinations in the context of a randomised controlled trial including their views on acceptability and tolerability of the intervention.
Open Access Article
Open access. Handgrip strength may provide an easily-administered marker of cognitive functional status. However, further population-scale research examining relationships between grip strength and cognitive performance across multiple domains is needed. Additionally, relationships between grip strength and cognitive functioning in people with schizophrenia, who frequently experience cognitive deficits, has yet to be explored.
The observed link between positive psychotic experiences (PE) and psychosis spectrum disorder (PSD) may be stronger depending on concomitant presence of PE with other dimensions of psychopathology. We examined whether the effect of common risk factors for PSD on PE is additive and whether the impact of risk factors on the occurrence of PE depends on the co-occurrence of other symptom dimensions (affective dysregulation, negative symptoms, and cognitive alteration).. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
Psychotic experiences (PEs) are common in childhood and have been associated with concurrent mental disorder and poorer global functioning. Little is known about the effects of childhood PEs on future functioning. We investigated the effects of childhood PEs on global functioning from childhood into early adulthood.. To read the full article, log in using your MPFT NHS OpenAthens details. SSOTP (legacy account) - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Symptoms of psychosis in patients with Alzheimer disease may be the expression of a pathological subtype associated with an accelerated cognitive and functional deterioration portending a hastened mortality.1 The proposed National Institute of Mental Health Research Domain Criteria initiative provides a framework for conceptualizing the common neurobiological underpinnings of symptom domains such as psychosis that transcend individual diagnostic categories to facilitate translational research.2 Gur et al3 suggest that highly implementable tasks measuring facial affective processing can be used to assay social cognitive integrity in psychotic disorders within the National Institute of Mental Health Research Domain Criteria framework. Although McLellan et al4 report that facial affective processing is degraded in Alzheimer disease, to our knowledge no published studies have investigated the association between this impairment and the psychotic phenotype. We report on facial affective processing performance in a longitudinal cohort of healthy elderly control individuals and participants with mild cognitive impairment (MCI) or Alzheimer disease at baseline, with and without symptoms of psychosis over the course of the study.https://blackwells.co.uk/bookshop/product/Evidence-Based-Assessment-in-ASD-Autism-Spectrum-Disorder-by-Kenneth-Aitken-author/9781849055291
This meta-analysis compares early intervention services with treatment as usual for patients with early-phase psychosis.. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
The management of schizophrenia is evolving towards a more comprehensive model based on functional recovery. The concept of functional recovery goes beyond clinical remission and encompasses multiple aspects of the patient’s life, making it difficult to settle on a definition and to develop reliable assessment criteria. In this consensus process based on a panel of experts in schizophrenia, we aimed to provide useful insights on functional recovery and its involvement in clinical practice and clinical research.
Open access. Very late (aged ≥60 years) onset schizophrenia-like psychosis occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy and risks of antipsychotic treatment. We investigated whether low-dose amisulpride (100 mg daily) is superior to placebo in reducing psychosis symptoms over 12 weeks and whether any benefit is maintained by continuing treatment after 12 weeks.
Open access. Comment. Robert Howard and colleagues should be commended for doing the first randomised controlled trial of an antipsychotic agent in patients diagnosed with very late-onset schizophrenia-like psychosis. Individuals with this diagnosis are notoriously difficult to engage in treatment.....